New drug cocktail aims to deepen remission in multiple myeloma patients
Disease control
Not yet recruiting
This Phase 3 trial tests whether adding the drug Teclistamab to a standard treatment regimen (Daratumumab, Lenalidomide, Bortezomib, Dexamethasone) improves outcomes for newly diagnosed multiple myeloma patients eligible for stem cell transplant. About 399 adults aged 18-70 will …
Phase: PHASE3 • Sponsor: University of Heidelberg Medical Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC